Baxter International (BAX) PT Raised to $88.00

Baxter International (NYSE:BAX) had its price target increased by stock analysts at JPMorgan Chase & Co. from $80.00 to $88.00 in a research note issued on Monday, The Fly reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 16.65% from the stock’s previous close.

Several other equities analysts have also issued reports on the stock. Wells Fargo & Co lifted their price target on shares of Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a report on Wednesday, April 3rd. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Barclays lifted their price target on shares of Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a report on Monday, April 15th. Cowen set a $75.00 price target on shares of Baxter International and gave the stock a “hold” rating in a report on Monday, April 22nd. Finally, Morgan Stanley lifted their price target on shares of Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, March 5th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Baxter International has a consensus rating of “Buy” and a consensus target price of $78.69.

Baxter International stock opened at $75.44 on Monday. The company has a quick ratio of 1.50, a current ratio of 1.83 and a debt-to-equity ratio of 0.50. Baxter International has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The company has a market cap of $38.77 billion, a PE ratio of 24.73, a P/E/G ratio of 1.79 and a beta of 0.96.



Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.08. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The firm had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.61 billion. During the same quarter in the previous year, the firm posted $0.70 earnings per share. The company’s revenue was down 1.7% on a year-over-year basis. On average, sell-side analysts predict that Baxter International will post 3.32 EPS for the current year.

In other news, SVP Giuseppe Accogli sold 38,297 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $76.78, for a total transaction of $2,940,443.66. Following the sale, the senior vice president now directly owns 70,001 shares of the company’s stock, valued at $5,374,676.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas T. Stallkamp sold 1,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $75.16, for a total transaction of $75,160.00. Following the sale, the director now directly owns 6,780 shares in the company, valued at $509,584.80. The disclosure for this sale can be found here. Insiders have sold 57,187 shares of company stock worth $4,447,619 over the last three months. Corporate insiders own 0.70% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Neuburgh Advisers LLC boosted its holdings in Baxter International by 149.6% in the first quarter. Neuburgh Advisers LLC now owns 19,808 shares of the medical instruments supplier’s stock valued at $1,611,000 after purchasing an additional 11,872 shares during the last quarter. Archford Capital Strategies LLC boosted its holdings in Baxter International by 60.0% in the first quarter. Archford Capital Strategies LLC now owns 800 shares of the medical instruments supplier’s stock valued at $65,000 after purchasing an additional 300 shares during the last quarter. Wealthfront Advisers LLC boosted its holdings in Baxter International by 11.0% in the first quarter. Wealthfront Advisers LLC now owns 13,614 shares of the medical instruments supplier’s stock valued at $1,107,000 after purchasing an additional 1,347 shares during the last quarter. Burney Co. boosted its holdings in Baxter International by 9.9% in the first quarter. Burney Co. now owns 8,706 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 783 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in Baxter International by 42.7% in the first quarter. Lazard Asset Management LLC now owns 5,222,634 shares of the medical instruments supplier’s stock valued at $424,651,000 after purchasing an additional 1,562,529 shares during the last quarter. 86.38% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What are economic reports?

The Fly

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.